马雷辛1调节高血压大鼠的脏和心脏脂质概况
Ruslan Bohovyk1, Olha Kravtsova1, Gunjan Upadhyay2
1Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, United States.
American journal of physiology. Renal physiology
|October 29, 2025
概括
马雷辛1 (MaR1) 没有降低血压,也没有防止盐引起的高血压中器官损伤. 然而,这种专门的预溶解媒介调节了心脏和脏中的脂质代谢,炎症和昼夜节律.
科学领域:
- 心血管生物学 心血管生物学
- 脂质中介体 脂质中介体
- 高血压研究 高血压研究
背景情况:
- 慢性炎症和目标器官损伤是高血压的关键特征.
- 专门的预溶解介质 (SPMs),如马雷辛1 (MaR1),是生物活性脂质,对于解决炎症至关重要.
- MaR1在心血管调节和血压控制方面显示出潜力.
研究的目的:
- 为了研究MaR1对达尔盐敏感 (SS) 鼠的盐诱导高血压和相关心脏脏损伤的影响.
- 探索MaR1对血压,心脏功能和脏健康的影响.
- 分析MaR1对脂质介质特征和器官特异性基因表达的影响.
主要方法:
- 在SS鼠群中,它们接受了高盐饮食,并接受了MaR1.1的治疗.
- 持续监测平均动脉压 (MAP) 和心率 (HR).
- 进行了心声学,组织学,脂质组分析和转录组分析.
主要成果:
- MaR1治疗没有显著改变MAP,HR,心脏结构或功能.
- 没有观察到心脏重塑,收缩性或纤维化的显著变化.
- 脂质组和转录组分析揭示了MaR1的免疫调节作用,改变了脂质介质,并影响了心脏和脏的昼夜通路,影响昼夜血压节律.
结论:
- 但MaR1并没有直接缓解盐引起的高血压,也没有预防心脏和脏结构损伤.
- 在高血压大鼠中,MaR1显著调节脂质代谢,炎症途径和昼夜基因表达.
- 这些发现表明MaR1在调节炎症和与心血管和脏疾病相关的昼夜节律方面的潜在治疗作用,需要进一步调查.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:29Hypertension II: Pathophysiology
698
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
698
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K